|
| Wednesday, February 28, 2024 |
|
|
Avance Clinical CEO는 US 바이오 기술 부문에 대한 "초록색 나무순"과 새로운 CRO 보고서에 대해 SCRIP와 대화했습니다 |
| more info >> |
|
|
Avance Clinical執行長談論了「美國生物技術產業的綠色新苗」和一份新的CRO報告 |
| Avance Clinical,作為一家屢獲殊榮的澳大利亞和北美市場領先的生物技術CRO公司，已經與SCRIP討論了他們 對美國生物技術產業的積極前景，這是在J.P.摩根醫療保健大會和生物技術展示會之後。 more info >> |
|
|
Avance Clinical首席执行官谈论了“美国生物技术行业的绿色新苗”和一份新的CRO报告 |
| Avance Clinical,作为一家屡获殊荣的澳大利亚和北美市场领先的生物技术CRO公司，已经与SCRIP讨论了他们对美国生物技术行业的积极前景，这是在J.P.摩根医疗保健大会和生物技术展示会之后。 more info >> |
|
|
Avance Clinical CEO Talks with SCRIP about US Biotech Sector "Green Shoots" and a New CRO Report |
| Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, has today spoken with SCRIP about their positive outlook for the US biotech sector following the J.P. Morgan Healthcare Conference and Biotech Showcase meetings. (read the full article here) more info >> |
|
| Wednesday, January 17, 2024 |
|
|
최신 분석에 따르면 미국의 바이오테크 기업 중 65%가 적절한 CRO파트너를 식별하는 데 어려움을 겪고 있습니다 |
| more info >> |
|
| Tuesday, January 16, 2024 |
|
|
最新的分析顯示，65%的美國生技公司在尋找合適的合約研究機構（CRO）合作夥伴方面面臨困難 |
| more info >> |
|
|
最新的分析显示，65%的美国生物技术公司在寻找合适的合同研究机构（CRO）合作伙伴方面面临困难 |
| more info >> |
|
| Friday, January 12, 2024 |
|
|
最新の分析によると、米国バイオテック企業の65％が適切なCROパートナーの特定に苦慮 |
| オーストラリアおよび北米市場をリードするバイオテクノロジー向け CRO であるアバンセ・クリニカルは、本日、新しい業界分析を発表しました。それによると、米国のバイオテクノロジー企業の60-65％が、医薬品開発プログラムの各段階において、適切な規模の CRO パートナーを特定することに課題を抱えていることが明らかになりました。また、これが臨床プログラムと予算に直接影響を与えていることもわかりました。 more info >> |
|
|
Latest Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner |
| Avance Clinical, the leading Australian and North American CRO for biotechs announced today that new industry analysis shows 60-65% of US biotechs face challenges identifying the right sized CRO partner that can deliver at every phase of their drug development program. The report found this directly affected clinical programs and budgets. more info >> |
|
| Thursday, October 19, 2023 |
|
|
아방스 클리니컬, 45개의 한국 생명 공학 기업 초청해 한국과 호주에서 미국으로 이어지는 글로벌레디 신약 개발 경로에 대한 설명회 개최 |
| more info >> |
|
|
|
|
